WO2001082858A3 - Novel compounds for the treatment of inflammatory and cardiovascular diseases - Google Patents

Novel compounds for the treatment of inflammatory and cardiovascular diseases Download PDF

Info

Publication number
WO2001082858A3
WO2001082858A3 PCT/EP2001/005043 EP0105043W WO0182858A3 WO 2001082858 A3 WO2001082858 A3 WO 2001082858A3 EP 0105043 W EP0105043 W EP 0105043W WO 0182858 A3 WO0182858 A3 WO 0182858A3
Authority
WO
WIPO (PCT)
Prior art keywords
butyl
inflammatory
treatment
isobutyl
tert
Prior art date
Application number
PCT/EP2001/005043
Other languages
German (de)
French (fr)
Other versions
WO2001082858A2 (en
Inventor
Wolf-Georg Forssmann
Helmut Drexler
Michael Walden
Bernhard Schieffer
Boris Schmidt
Original Assignee
Ipf Pharmaceuticals Gmbh
Wolf-Georg Forssmann
Helmut Drexler
Michael Walden
Bernhard Schieffer
Boris Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipf Pharmaceuticals Gmbh, Wolf-Georg Forssmann, Helmut Drexler, Michael Walden, Bernhard Schieffer, Boris Schmidt filed Critical Ipf Pharmaceuticals Gmbh
Priority to AU2001267404A priority Critical patent/AU2001267404A1/en
Publication of WO2001082858A2 publication Critical patent/WO2001082858A2/en
Publication of WO2001082858A3 publication Critical patent/WO2001082858A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns a compound having structural formula (I), wherein R1 represents H, substituted or unsubstituted alkyl or acyl groups, especially methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert. Butyl; X = halogen or OH; R2 represents H, substituted or unsubstituted alkyl or acyl groups, especially methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert. butyl, halogen or OH; R3 represents H, substituted or unsubstituted alkyl or acyl groups, especially methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert. butyl, halogen or OH; R4 represents H, substituted or unsubstituted alkyl or acyl groups, especially methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert. butyl or is a metal radical, especially an alkali cation.
PCT/EP2001/005043 2000-05-04 2001-05-04 Novel compounds for the treatment of inflammatory and cardiovascular diseases WO2001082858A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001267404A AU2001267404A1 (en) 2000-05-04 2001-05-04 Novel compounds for the treatment of inflammatory and cardiovascular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10021615 2000-05-04
DE10021615.3 2000-05-04

Publications (2)

Publication Number Publication Date
WO2001082858A2 WO2001082858A2 (en) 2001-11-08
WO2001082858A3 true WO2001082858A3 (en) 2002-06-27

Family

ID=7640695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005043 WO2001082858A2 (en) 2000-05-04 2001-05-04 Novel compounds for the treatment of inflammatory and cardiovascular diseases

Country Status (2)

Country Link
AU (1) AU2001267404A1 (en)
WO (1) WO2001082858A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002233197A1 (en) * 2000-11-23 2002-06-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of modulators of eukaryotic signal transduction pathways for the treatment of helicobacter infections
US20040097565A1 (en) * 2001-01-29 2004-05-20 Terashita Zen-Ichi Analgesic and antiinflammatory drugs
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
ATE393764T1 (en) 2003-03-17 2008-05-15 Teva Pharma POLYMORPHOUS FORMS OF VALSARTAN
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
WO2004094392A1 (en) 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
JP5395905B2 (en) 2008-09-02 2014-01-22 エルダー・ファーマシューティカルズ・リミテッド Anti-inflammatory compounds
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000977A2 (en) * 1990-07-13 1992-01-23 E.I. Du Pont De Nemours And Company 4-alkylimidazole derivatives
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1992020342A1 (en) * 1991-05-15 1992-11-26 E.I. Du Pont De Nemours And Company Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
EP0581003A1 (en) * 1992-06-26 1994-02-02 Bayer Ag Imidazolyl substituted cyclohexane derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1992000977A2 (en) * 1990-07-13 1992-01-23 E.I. Du Pont De Nemours And Company 4-alkylimidazole derivatives
WO1992020342A1 (en) * 1991-05-15 1992-11-26 E.I. Du Pont De Nemours And Company Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
EP0581003A1 (en) * 1992-06-26 1994-02-02 Bayer Ag Imidazolyl substituted cyclohexane derivatives

Also Published As

Publication number Publication date
AU2001267404A1 (en) 2001-11-12
WO2001082858A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
BE2018C008I2 (en)
WO1999002514A3 (en) Epothilone derivatives
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
WO2003048148A3 (en) Statin-like compounds
EP0945452A4 (en) Sugar compounds, gelling agents, gelling agent compositions, processes for the preparation of them, and gel compositions
CA2264824A1 (en) A process for preparing 2-amino malonic acid derivatives and 2-amino-1,3-propanediol derivatives, and intermediates for preparing the same
EP1288199A4 (en) Mmp-12 inhibitors
WO2004014913A3 (en) Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
ZA911502B (en) A pharmaceutical solution
WO2001082858A3 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU3744397A (en) Total synthesis of antitumor acylfulvenes
WO2004050663A3 (en) An improved process for the preparation of cefuroxime sodium
HU9904634D0 (en) New thiaazolidine-derivatives
PL340658A1 (en) Derivatives of biphenylamidine
DE69529619D1 (en) Pyrimidinylpyrazolderivate
ES2093037T3 (en) DERIVATIVES OF BETA-LACTAMA AND ITS PREPARATION.
AU6117598A (en) Compounds
IL154014A0 (en) Process for the preparation of 2-aminoethylpyridines
AU3785897A (en) Neuraminic acid compound
ES2185599T3 (en) PREPARATION OF INTERMEDIARIES OF IMIDAZODIACEPINA.
WO2002024690A8 (en) Efficient process for the preparation of a factor xa inhibitor
DK0618234T3 (en) Process for the preparation of semi-synthetic glycosaminoglycans with heparin or heparan structure modified at the 2-position of alpha-L-iduron-2-O-sulfate acid
WO2001083423A3 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof
WO2001052824A3 (en) Use of particular compounds for prophylaxis and treatment of hepatitis c
EP1026154A3 (en) Preparation process of difluoroacetophenone derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP